Event Details

In this webinar, three speakers will share their perspective on the using of causal inference methodology in the analysis of RCT data. The audience will be presented with ideas and opportunities on why and how to apply causal inference principles / techniques in their work. And more importantly how causal approaches can help evaluating evidence for answers to causal-by-nature scientific questions.


First, Kaspar Rufibach (Merck) will share his perspectives on opportunities to apply causal methods. Next, Susan Gruber (TL revolution) will discuss targeted learning as a framework to address causal questions and the importance of sensitivity analyses. Finally, Florian Lasch (EMA) will discuss both the importance of the causal inference angle in determining estimands, and will discuss a case study.


The webinar will end with a panel discussion.


Who is this event intended for? Applied statisticians, and people genuinely interested in applying state-of-the-art statistical methodology.


What is the benefit of attending? Increased understanding and insights in causal inference principles and methodology.

Speakers

  • Kaspar Rufibach (Biostatistician at Merck KGaA)

    Kaspar Rufibach

    Biostatistician at Merck KGaA

    Kaspar Rufibach is a biostatistician who is passionate about supporting statisticians and drug developers to continuously challenge the status quo, with the aim of improving the drug development process, making it more efficient, and enabling access.

    Kaspar has co-founded and co-leads the special interest group “Estimands in oncology” which has (as of August 2024) more than 100 members from 50 institutions globally. He has also co-founded and co-leads the EFSPI statistical methodology leader group which has 14 members from 14 companies. He regularly interacts with regulators globally on various joint projects.

    Kaspar’s research interests are methods to optimize study designs, platform trials, advanced survival analysis, probability of success, estimands and causal inference, and estimation of treatment effects in subgroups. Kaspar received training and worked as a statistician at the Universities of Bern, Stanford, and Zurich. From 2012 until 2024 he worked at Roche before joining Merck KGaA in October 2024 to co-lead its Advanced Biostatistical Science group.
    More on the oncology estimand WG: http://www.oncoestimand.org
    More on the EFSPI statistical methodology leaders group: https://efspieurope.github.io/efspi/methods/methods_intro.html
    More on Kaspar: http://www.kasparrufibach.ch

    view more
  • Susan Gruber (Co-Founder of TL revolution)

    Susan Gruber

    Co-Founder of TL revolution

    Susan Gruber, co-founder of TL Revolution and Founder of Putnam Data Sciences, is a biostatistician and computer scientist specializing in causal inference and predictive modeling. Her work focuses on improving methods and tools for generating robust real-world evidence to support biopharmaceutical and medical decision-making through Targeted Learning. Her tmle R package on CRAN has over 70,000 downloads worldwide.

    view more
  • Florian Lasch (Biostatistic Specialist at European Medicines Agency)

    Florian Lasch

    Biostatistic Specialist at European Medicines Agency

    Florian is a Biostatistician with a degree in mathematics and a PhD from Hannover Medical School. Florian works as a Biostatistics Specialist at the European Medicines Agency, providing scientific support to development and evaluation throughout all stages of marketing authorisation assessments of medicinal products, and leads the ACT EU Priority Action on Clinical Trial Methodologies and the EMA Estimands Implementation Group.

    view more

Tickets

PSI Member
Member Price Complimentary
PSI Non-Member
Standard Price Complimentary

Community

Connect with 313 people attending this event